Abstract:First discovered in Wuhan, China, SARS-CoV-2 is a highly pathogenic novel coronavirus, which rapidly spread globally and became a pandemic with no vaccine and limited distinctive clinical drugs available till March 13th, 2020. Ribonucleic Acid interference (RNAi) technology, a gene-silencing technology that targets mRNA, can cause damage to RNA viruses effectively. Here, we report a new efficient small interfering RNA (siRNA) design method named Simple Multiple Rules Intelligent Method (SMRI) to propose a new solution of the treatment of COVID-19. To be specific, this study proposes a new model named Base Preference and Thermodynamic Characteristic model (BPTC model) indicating the siRNA silencing efficiency and a new index named siRNA Extended Rules index (SER index) based on the BPTC model to screen high-efficiency siRNAs and filter out the siRNAs that are difficult to take effect or synthesize as a part of the SMRI method, which is more robust and efficient than the traditional statistical indicators under the same circumstances. Besides, to silence the spike protein of SARS-CoV-2 to invade cells, this study further puts forward the SMRI method to search candidate high-efficiency siRNAs on SARS-CoV-2's S gene. This study is one of the early studies applying RNAi therapy to the COVID-19 treatment. According to the analysis, the average value of predicted interference efficiency of the candidate siRNAs designed by the SMRI method is comparable to that of the mainstream siRNA design algorithms. Moreover, the SMRI method ensures that the designed siRNAs have more than three base mismatches with human genes, thus avoiding silencing normal human genes. This is not considered by other mainstream methods, thereby the five candidate high-efficiency siRNAs which are easy to take effect or synthesize and much safer for human body are obtained by our SMRI method, which provide a new safer, small dosage and long efficacy solution for the treatment of COVID-19. Supplementary information: The online version contains supplementary material available at 10.1007/s11390-021-0826-x.

An Effective Platform for SARS-CoV-2 Prevention by Combining Neutralization and RNAi Technology

Robust and durable prophylactic protection conferred by RNA interference in preclinical models of SARS-CoV-2

Therapeutic and Prophylactic Potential of Small Interfering RNAs Against Severe Acute Respiratory Syndrome

Introduction to RNA Vaccines Post COVID-19

A coronavirus-mimic mesoporous silica nanosystem enables efficient targeted delivery of siRNA for anti-SARS-CoV‐2

Inhibition Of Sars-Cov Gene Expression By Adenovirus-Delivered Small Hairpin Rna

Functionalized protein microparticles targeting hACE2 as a novel preventive strategy for SARS-CoV-2 infection

Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles

A Convenient and Biosafe Replicon with Accessory Genes of SARS-CoV-2 and Its Potential Application in Antiviral Drug Discovery

SMRI: A New Method for siRNA Design for COVID-19 Therapy

RNAi Technology and Investigation on Possible Vaccines to Combat SARS-CoV-2 Infection

Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses

Development of a highly stable, active small interfering RNA with broad activity against SARS-CoV viruses

An intranasally delivered ultra-conserved siRNA prophylactically represses SARS-CoV-2 infection in the lung and nasal cavity.

A Multifunctional Neutralizing Antibody‐Conjugated Nanoparticle Inhibits and Inactivates SARS‐CoV‐2

Repurposing Niclosamide as a Novel Anti-SARS-CoV-2 Drug by Restricting Entry Protein CD147

From a genome-wide screen of RNAi molecules against SARS-CoV-2 to a validated broad-spectrum and potent prophylaxis

Inhibition of Severe Acute Respiratory Syndrome Virus Replication by Small Interfering RNAs in Mammalian Cells

Preventing Covid59

A DNA-based non-infectious replicon system to study SARS-CoV-2 RNA synthesis

siRNA Therapeutics for the Therapy of COVID-19 and Other Coronaviruses